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Abstract
Background: High levels of depressive symptoms often occur among individuals that use or that are dependent
on methamphetamine (MA). Thailand is currently experiencing an epidemic of MA use among youth.
Understanding the nature of the relationship between depressive symptoms and MA use and identifying those
most at risk can further understanding of prevention and treatment options for youth who use MA and present
with depressive symptoms.
Methods: In 2011, we conducted a cross sectional epidemiologic study that examined associations between MA
use and high levels of depressive symptoms among adolescents and young adults aged 14–29 living in Chiang Mai
province, Thailand. A combination of cluster and systematic sampling was conducted to obtain a study sample of
participants actively recruited in Chiang Mai province. Depressive symptoms were measured using a Thai translation
of the Centers for Epidemiologic Studies Depression scale (CES-D). The independent variables measured reported
lifetime and recent MA use within the past 3 months. Multivariate logistic regression models were used to assess
associations between MA use and high levels of depressive symptoms.
Results: Approximately 19 % (n = 394) of the sample reported ever having consumed MA and 31 % (n = 124) of
lifetime users reported recent MA use within the past 3 months. Recent MA use was associated with high levels of
depressive symptoms (aPOR recent use: 2.60, 95 % CI: 1.20, 5.63).
Conclusions: This is one of the first studies to examine the association between MA use and high levels of
depressive symptoms in a general Thai population. The odds of having high levels of depressive symptoms was
significantly greater among recent MA users compared to non-users. These findings support the need for policies,
programs and interventions to prevent and treat depressive symptoms presenting among MA using Thai
adolescents and young adults in rural Chiang Mai province, Thailand to aid in cessation of MA use. Furthermore,
additional research is needed to investigate treatment options for adolescents and young adults in Thailand that
use MA and present with high levels of depressive symptoms.
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Key messages
 This research demonstrates an association between
methamphetamine and depressive symptoms,
controlling for confounding, among a general
population of Thai adolescents and young adults in
Chiang Mai Province, Thailand.
 This research provides evidence to support the need
for interventions to target this comorbidity among
young people in rural areas of Thailand that are
exposed to methamphetamine and serves as a
foundation for further research into effective
treatment of depressive symptoms and cessation of
methamphetamine use among youth in rural
Northern Thailand.
Background
Methamphetamine (MA) use became ubiquitous as a
recreational drug among adolescents and young adults
in Thailand beginning in the mid-1990s [1, 2]. The
popularity of recreational MA use among Thai adoles-
cents and young adults, the perceptions about MA use
being normative or fashionable, exposure to MA from
peers, personality traits such as curiosity and sensation-
seeking, coping mechanisms and functional needs led to
the emergence of MA as a significant public health
problem among this population [3, 4]. Indeed, MA use
has a lasting psychosocial impact not only on individ-
uals, but entire communities [5]. MA became commonly
referred by Thais as “ya-ba,” or crazy pill, due to its abil-
ity to induce psychosis and other psychological symp-
toms [6]. By 2003, an estimated 3 million Thais or 5 %
of the population were reported to be chronically
dependent on MA [7].
MA use has been shown to be associated with se-
vere psychological harms and commonly is associated
with depression [8]. Studies in various settings have
found a high prevalence of MA users reporting a life-
time history of depression, with prevalence estimates
ranging between 50 % of men and 68 % of women
and 57 % of MA users reporting the presence of de-
pressive symptoms in the past year compared to 32 %
among non-users [9, 10]. Another study conducted
among MA users entering treatment in Australia ob-
served that 40 % (n = 400) of study participants had a
diagnosis of major depression within a year prior to
admission, and another 44 % met the criteria for
major depression but were excluded because their de-
pressive symptoms were attributed to drug depend-
ence [11]. In a study of young Thai MA users aged
18–25 years, authors observed a prevalence of 35 %
of participants presenting with high levels of depres-
sive symptoms [12]. Most studies are limited by de-
sign or methodology because they have assessed the
prevalence of depression among amphetamine or MA
users using various instruments to measure depressive
symptoms, and most have examined limited data
among health seeking populations that may not be
representative of all users. Most of these studies have
not been conducted among populations in low- and
middle-income countries and only one was conducted
among Thai youth. No studies of general Thai popu-
lations in rural areas have been conducted to our
knowledge.
The nature of the relationship between depressive
symptoms and MA use, abuse and dependence (i.e.,
drug-induced depressive symptoms, self-medicating to
alleviate depressive symptoms, etc.) and the preva-
lence of these comorbid conditions have public health
implications for treatment and prevention that have
received little attention outside of the United States.
Thailand, which is currently experiencing an MA epi-
demic, warrants further attention in terms of preven-
tion and treatment of these comorbid conditions [12].
Populations residing in Thailand’s Northern provinces,
including Chiang Mai province, are the most access-
ible to MA trafficking routes since the drug is distrib-
uted across the borders separating Thailand from
Laos and Burma, and many residents are involved in
the drug trade [7]. High levels of depressive symp-
toms may be greater than average among Thai adoles-
cents and young adults in these rural areas within the
Golden Triangle due to exposure to and participation
in the MA market and the extensive use of MA
within social networks. However, research has yielded
little documentation of high levels of depressive
symptoms comorbid to MA use in Thailand and little
is known of evidenced-based or culturally-relevant in-
terventions to prevent and treat both disorders. Fur-
thermore, mental health and substance abuse research
have received little attention in Thailand compared
with the magnitude of publications dedicated to med-
ical research [13].
Our research attempts to add to the growing body of
knowledge of mental health and substance use re-
search emerging in Thailand using probabilistic sam-
pling methods that improve the generalizability of
results to the general population of adolescents and
young adults in rural areas of northern Thailand
where MA distribution and use is prominent. The pri-
mary purpose of this study is to describe the preva-
lence of depressive symptoms among MA users and to
assess the association between MA use and depressive
symptoms among Thais 14 – 29 years of age residing
in rural areas of northern Thailand in close proximity
to the Burma and Lao borders. We hypothesize that
there will be an association between MA use and high
levels of depressive symptoms.
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Methods
Study population
This study uses data from a baseline survey of behavioral
data administered prior to the start of a community
cluster-randomized community mobilization trial in six
districts of rural Chiang Mai province in northern
Thailand. Baseline data collection took place within a com-
plex combination of nested cluster and systematic random
sampling, beginning at the district level and proceeding
with cluster sampling of sub-districts, communities and vil-
lages. Next, systematic random sampling was conducted to
sample from a frame consisting of households and finally
individuals, which yielded a representative sample of ado-
lescents and young adults aged 14–29 years of age. The re-
sponse rate during recruitment procedures was over 90 %
(n = 2055). The study has been described in detail else-
where [14]. This research was approved by the Institutional
Review Board (IRB) at the Johns Hopkins Bloomberg
School of Public Health, the Human Experimentation
Committee at the Research Institute for Health Sciences,
Chiang Mai University and the Faculty of Medicine, Re-
search Ethics Committee, Chiang Mai University, Thailand.
Written informed consent for participation in this study
was obtained from participants or, if participants were ado-
lescents 14–17 years of age, informed assent and informed
consent from a parent or guardian was obtained.
Case definition
Depressive symptoms were measured by using the Center
for Epidemiologic Studies Depression Scale (CES-D) [15].
The CES-D contains 20 items that measure self-reported
symptoms of depression experienced for a duration of at
least 2 weeks. Participants report the frequency of experien-
cing each item on a scale ranging from 0, indicating that
they experience that symptom rarely or none of the time,
and 3, indicating that they experience that symptom most
or all of the time. Items are summarized during the statis-
tical analysis to obtain a score capable of ranging from 0 to
60 and scores of the four positive items were reversed prior
to generating total scores. A cutoff of ≥ 22 was used to
define high levels of depressive symptoms among Thais be-
cause this cutoff has been previously validated in Thailand
[16]. This cutoff was based on an evaluation of the CES-D
against structured interviews, conducted by psychiatrists, of
adolescent Thai males aged 15–18; participants with vali-
dated depression, based on interviews with psychiatrists,
had significantly higher CES-D scores when compared to
participants without depression. The study determined a
cutoff of ≥ 22 produced optimal sensitivity and specificity
(sensitivity = 72 %, specificity = 85 %). To our knowledge,
no other scale used to measure depressive symptoms has
been validated among a general Thai population of adoles-
cents and young adults with ages similar to the population
in this study [12, 16, 17].
Variables
Items used to measure drug use behaviors were obtained
from portions of the Risk Behavior Assessment (RBA)
questionnaire [18]. MA use patterns were defined as life-
time use if the participant reported ever using MA and
defined as recent use if the participant reported using MA
in the past 3 months. Responses derived from these two
questions were coded as binary variables whereby 0 indi-
cated no use and 1 indicated use of MA on at least 1 day
during their lifetime or within the past 3 months. Con-
founders identified from the literature were measured and
included age, gender, educational attainment, lifetime alco-
hol consumption, recent alcohol consumption and the use
of illicit drugs other than MA within the participant’s life-
time or in the past 3 months prior to baseline [12]. To
measure lifetime and recent alcohol consumption within
the past 30 days, we used portions of the Alcohol Use
Disorders Identification Test (AUDIT) [19]. Illicit drugs in-
cluded: ice, heroin, opium, valium, domicum, barbiturates,
marijuana, ketamine, glue and kratom, another illicit drug
commonly used in Thailand [20]. Responses on reported
illicit drug use were summed and coded as a binary variable
similar to responses obtained from questions about MA
use. Age was grouped into two categories defined by ado-
lescents being 14–17 years of age and young adults being
those 18–29 years of age; young adults were thought to be
at different developmental stages compared to adolescents.
Adolescents may vary in expression of depressive symp-
toms and endorsement of certain items on the CES-D
when compared to young adults [21]. Measures of educa-
tional attainment included reports of never having gone to
school or the participant’s self-report of having completed
primary school, secondary school, high school, vocational
school or of having earned a college degree or more. Add-
itional measures of education included items to assess
whether the participant was currently attending school.
Statistical analysis
Comparisons were made between sociodemographic and
substance use variables between those categorized as hav-
ing high levels of depressive symptoms and those having
low levels of depressive symptoms using chi-squared tests.
Crude logistic regression was implemented to examine
associations between lifetime and recent MA use and high
levels of depressive symptoms. Crude logistic regression
models were also conducted to assess associations be-
tween sociodemographic or drug use variables and high
levels of depressive symptoms to assess potential con-
founders. Covariates that achieved a level of statistical sig-
nificance of p <0.10 and variables that have been identified
in the literature as confounders were included in the final
multivariate logistic regression model. Because the data
were cross-sectional, prevalence odds ratios (POR) with
95 % confidence intervals were estimated to compare the
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odds of having high levels of depressive symptoms be-
tween reported MA users against a reference group of ab-
stainers. Due to clustering of individuals by district, a
sensitivity analysis was performed to account for the clus-
tered nature of the data by incorporating the “xtlogit”
command in Stata as an extension of multivariate logistic
regression models [22]. Interactions by gender and use of
illicit drugs other than MA were incorporated into models
to assess effect modification. The prevalence of MA use
and of high levels of depressive symptoms among lifetime
and recent MA users was also determined. Statistical ana-
lyses were conducted using Stata Intercooled version 10.1
(Stata Corp., College Station, Texas).
Results
Descriptive statistics can be found in Table 1. The sam-
ple (n = 2055) consisted predominately of young adults
(n = 1247) with a median age of 20 who were predomin-
antly single, separated, widowed or divorced (79 %), of
Thai ethnicity (100 %), and Buddhist (99 %) and re-
ported living primarily at their parent’s house during the
past 3 months (77 %), currently attending school (59 %),
and currently being unemployed (56 %). Approximately
19 % reported ever having consumed MA (n = 394) with
31 % of lifetime users reported recent MA use within
the past 3 months (n = 124). Relative to those without
reported baseline lifetime MA use, individuals reporting
ever having consumed MA were significantly more likely
to be male (p < 0.001).
Approximately 9 % of the sample (N = 2055) met cri-
teria for exhibiting high levels of depressive symptoms.
The mean CES-D score estimated for the entire sample
was 17.01 (S.D.: 6.39). The range of CES-D scores was
0–57. Among lifetime MA users, the prevalence of high
levels of depressive symptoms was approximately 12 %
(n = 46) compared to 8 % of abstainers and 16 % among
recent MA users compared to 10 % of abstainers. Rela-
tive to those who reported no lifetime MA use at base-
line (Table 2), individuals who reported having ever used
MA in their lifetime were more likely to have high levels
of depressive symptoms using the recommended Thai
cutoff score of ≥ 22 on the CES-D scale, but this meas-
ure of association did not reach statistical significance
(POR: 1.48, CI: 1.04–2.11; p <0.05). Of those who re-
ported a history of lifetime MA use, recent MA users
were almost twice as likely to have high levels of depres-
sive symptoms compared to nonusers (POR: 1.80, CI:
0.96–3.38; ρ <0.10). Compared to those without high
levels of depressive symptoms, those defined as having
high levels of depressive symptoms at baseline were
more likely to be female (p < 0.001). Table 1 also de-
scribes the distributions of high levels of depressive
symptoms among various subgroups of the sample. Add-
itionally, the proportion of female MA users having high
levels of depressive symptoms was substantially higher
than male MA users, with 23 % of females who reported
ever using MA experiencing high levels of depressive
symptoms compared to 9 % of males (p < 0.01).
We examined demographic and behavioral variables
identified in the literature as confounders. In our study,
associations between high levels of depressive symptoms
and age, gender and current school attendance were sta-
tistically significant (Table 2). In other words, the odds of
having a high level of depressive symptoms was greater
among females, young adults, individuals not currently
attending school, and MA users. Due to concerns about
collinearity, we used current school attendance in the final
model rather than educational attainment. Multivariate
logistic regression (Table 3) demonstrated significant, in-
dependent associations between recent MA use and high
levels of depressive symptoms (POR: 2.60, 95 % CI: 1.20,
5.63). Statistical models which accounted for clustering by
using the “xtlogit” command in Stata generated similar
prevalence odds ratios (data not shown) and there was no
evidence for effect modification of high levels of depres-
sive symptoms by MA use and polydrug use or by MA
use and gender.
Discussion
High levels of depressive symptoms were associated with
reported recent MA use. This study quantifies the preva-
lence of high levels of depressive symptoms comparing MA
users to non-MA users in a general population of adoles-
cent and young Thai adults. The study also examines the
association between depressive symptoms and MA among
Thai youth living in rural areas using a complex sampling
strategy consisting of multistage, community-clustered and
systematic random sampling. Such a study sampling
method was necessary given the ubiquity of MA trafficking
and distribution in this region. Consistent with our hypoth-
esis, high levels of depressive symptoms were positively
associated with MA use.
We observed high rates of depressive symptoms in the
entire sample and among MA users. In our study, ap-
proximately 12 % of individuals who reported ever using
methamphetamine had high levels of depressive symp-
toms. The prevalence of depression among MA users is
comparable with the estimates reported among psychos-
timulant users in the U.S. [23]. There are several pos-
sible explanations for observing this association. First,
this population could possibly be suffering psychological
sequelae of chronic MA use. Second, adolescents and
young adults could initiate MA use as an attempt to
self-medicate an existing depression [24]. The historical,
social, economic and political context existing within
Thailand is such that there is a change to a more competi-
tive, global market-driven economy from a rural, agrarian
lifestyle. This new social and political environment is
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replacing traditional family values, and these changes may
initiate the onset of stress and lead to the development of
depression among youth who perceive they are responsible
for competing in the global economy [4]. Moreover, in a
region where the drug market renders MA to be wide-
spread, accessible and inexpensive, economic stressors
may lead to the onset of depression and subsequently
lead to MA use by adolescents and young adults to self-
medicate [25].
The relationship between MA and depression could
potentially be bidirectional. Symptoms indicative of de-
pression could lead to initiation and continuation of MA
use. Consequently, affective and motivational dysfunc-
tion related to depression can occur as a result of
Table 1 Characteristics of the Sample and CES-D Categories
Baseline Characteristics High Levels of Depressive Symptoms Low Levels of Depressive Symptoms All p-
valueN = 182 N = 1873 N = 2,055
N (%) N (%) N (%)
Gender
Males 64 (35.2 %) 987 (52.7 %) 1051 (51.1 %) <0.05
Age
14–17 58 (31.9 %) 750 (40.0 %) 808 (39.3 %)
18–29 124 (68.1 %) 1123 (60.0 %) 1247 (60.7 %) <0.05
Residence
Parent’s house 145 (79.7 %) 1441 (76.9 %) 1586 (77.2 %)
Other 37 (20.3 %) 432 (23.1 %) 469 (22.8 %) 0.401
Marital status
Single, widowed, separated, divorced 133 (73.1 %) 1491 (79.6 %) 1624 (79.0 %)
Currently married or cohabitating 49 (26.9 %) 382 (20.4 %) 431 (21.0 %) <0.05
Religion
Buddhism 181 (99.5 %) 1850 (98.8 %) 2031 (98.8 %) ____
Ethnicity
Thai 182 (100 %) 1871 (99.9 %) 2053 (99.9 %) ____
Current school attendance
Yes 89 (48.9 %) 1123 (60.0 %) 1212 (59 %)a <0.05
Employment status
Full-time, part-time, irregular work 88 (48.4 %) 738 (41.0 %) 817 (41.4 %)b 0.236
MA Use
Lifetime use 46 (25.3 %) 348 (18.6 %) 394 (19.2 %) <0.05
Recent use 20 (3.5 %) 104 (29.9 %) 124 (31.5 %)c <0.10
Illicit Substances
Lifetime use 41 (22.5 %) 341 (18.2 %) 382 (18.5 %) 0.15
Recent Use 5 (12.2 %) 74 (21.7 %) 79 (20.7 %)d 0.16
Alcohol Consumption
Lifetime use 131 (72.0 %) 1370 (73.1 %) 1501 (73.0 %) 0.74
Recent use 85 (64.9 %)e 858 (62.6 %) 943 (62.8 %)e 0.61
Table 1 describes the distributions of the general characteristics of the total sample and two subpopulations of the sample defined by high and low depressive
symptoms based on the recommended. Thai cutoff of ≥ 22. Recent MA and polydrug use is defined as the proportion of lifetime users reporting recent substance
use. Illicit substances is defined as all other illicit substances other than MA and includes use of one or more of the following: heroin, opium, valium, domicum,
barbiturates, marijuana, ketamine, glue and kratom
p-values indicate chi-squared test for independence between high/low levels of depressive symptoms and sample characteristics. Frequencies and proportions of
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Table 3 Adjusted prevalence ratios derived from logistic regression for high levels of depressive symptoms, MA use and covariates
to describe odds of high levels of depressive symptoms among adolescents and young adults who use MA in northern rural
Thailand
Adjusted prevalence odds ratioa Confidence intervals Ρ-value
Lifetime MA Risk Behavior (N = 2054)
Lifetime MA use 1.61 0.98–2.64 0.06
Lifetime polydrug use N = 2054 1.45 0.87–2.43 0.16
Lifetime alcohol consumption 0.82 0.55–1.23 0.33
Gender 2.63 1.82–3.80 <0.001
Age 1.16 0.75–1.77 0.49
Current school attendance 1.35 0.92–1.99 0.13
Recent MA Risk Behavior (n = 266)
Recent MA use 2.60 1.20–5.63 <0.05
Recent polydrug use 0.53 0.17–1.67 0.23
Recent alcohol consumption 0.85 0.26–2.75 0.79
Gender 3.31 1.28–8.55 <0.05
Age 0.93 0.30–2.87 0.90
Current school attendance 1.19 0.43–3.33 0.74
CES-D denotes the Center for Epidemiologic Studies Depression Scale (Radloff [15])
aAdjusted for gender, age, current school attendance, lifetime or recent polydrug use of any illicit drug other than MA use within the past 3 months, and lifetime
or recent alcohol consumption of any beverage within the past 30 days. Reported measures of lifetime alcohol and polydrug use are included in regression
models assessing the relationship between lifetime MA use and high levels of depressive symptoms. Recent alcohol consumption and polydrug use are included
in regression models assessing the association between recent MA use and high levels of depressive symptoms. Polydrug use defined as reported use of one or
more of the following: ice, heroin, opium, valium, domicum, barbiturates, marijuana, ketamine, glue and kratom
Table 2 Crude Prevalence Odds Ratios Indicating Odds of Endorsing High Levels of Depressive Symptoms among Demographic
and Drug Use Behavior Characteristics
Crude prevalence odds Ratio Confidence Interval ρ-value
Age 1.43 1.03–1.98 <0.05
Gender 2.05 1.50–2.82 <0.001
Highest level of educationa 0.93 0.66–1.33 0.71
Current school attendance 1.57 1.15–2.13 <0.05
Employedb 1.21 0.88–1.65 0.24
Residence 0.93 0.66–1.33 0.71
Lifetime MA use 1.48 1.04–2.11 <0.05
Recent MA usec 1.80 0.96–3.38 <0.10
Lifetime polydrug use 1.31 0.91–1.89 0.15
Recent polydrug used 0.50 0.19–1.32 0.16
Lifetime alcohol consumption 0.94 0.67–1.32 0.74
Recent Alcohol consumptione 1.10 0.76–1.60 0.61
Age categorized into two groups: 14–17 years of age and 18–29 years of age
Employed categorized into Full-time, part-time or irregular work compared to unemployed. Highest level of education categorized primary, secondary or high
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chronic use and withdrawal, which could possibly con-
tribute to the continuation of MA use for the mainten-
ance of depressive symptoms. This maintenance of
depressive symptoms is prolonged due to sustained use
of drugs in greater amounts, more frequent use or
injecting in order to relieve depressive symptoms result-
ing from chronic use [26]. One longitudinal epidemio-
logical study attempted to address the nature of this
relationship by assessing the temporality of MA use and
depressive symptoms among MA users in Thailand. This
study concluded that depressive symptoms were a con-
sequence of MA use [12].
Of note is the observed independent crude and ad-
justed association between gender and high levels of de-
pressive symptoms. Of the participants that endorsed
high levels of depressive symptoms, 6 % were male com-
pared to 12 % of females. On the other hand, approxi-
mately 33 % of males reported recent MA use compared
to 23 % of females and explains the lack of effect modifi-
cation by gender. We had hypothesized a priori that
gender would be a confounder since previous literature
has documented higher levels of depressive symptoms in
females, whether induced by substance use or independ-
ent of substance use, and has documented that males
are more likely to use illicit substances than females.
Other covariates were added to the multivariate model if
they met the aforementioned criteria for being included,
but had little effect on the estimate describing MA use
and high levels of depressive symptoms.
Treatment of depressive symptoms presenting with
substance use and dependence of MA has been prob-
lematic. Several randomized controlled trials conducted
to evaluate the efficacy of various antidepressants in re-
lieving depressive symptoms and achieving cessation
have found treatment to be inconsistently efficacious
among individuals who were dependent on or abused
MA or cocaine [27–30]. All of these trials have been
conducted in urban areas of the United States, and most
involve small sample sizes. An additional review of treat-
ment options specific to MA users presenting with de-
pression reveals a large gap in knowledge of effective,
sustainable treatment options whether treatment options
are psychological approaches, pharmacological ap-
proaches or both [31].
There are some limitations inherent in this study that
must be considered. First, the study was cross-sectional. A
temporal relationship between MA use and high levels of
depressive symptoms cannot be established. Second, there
could be underreporting of stigmatized behaviors and
stigmatization of MA use by Thai communities remains a
concern among youth [3]. Misclassification could result
from self-reports, but our interviews were administered
using Audio computer-assisted self-interview (ACASI)
software where previous studies have shown little effect
on internal validity in similar populations [32]. Another
limitation that should be considered is that the parent
study was not implemented solely to assess our hypoth-
esis. Therefore, numerous possible other (unmeasured)
confounders such as other psychiatric disorders were not
included in the survey. However, such disorders would be
rare in this population. Different time frames were used to
measure recent MA use, polydrug use and alcohol con-
sumption. We did not include measures of illicit drug
polydrug or MA use within the past 30 days in our base-
line survey. However, inferences about the independent
association between high levels of depressive symptoms
and recent MA use within the past 3 months were similar
in our univariate and multivariate models when recent
polydrug and alcohol use were incorporated into the
model and the association supports previous findings.
Last, the Thai cutoff of ≥ 22 was based on research among
a limited sample size and included only Thai adolescent
males.
This study presents strengths relevant for drawing
public health implications. The large sample size of the
study population, the probabilistic sampling method-
ology, and the extensive coverage of several communities
within sub-districts are strong characteristics of this
study. Relatively little research has been conducted in
Thailand that quantifies the prevalence of high levels of
depressive symptoms among adolescents and young
adults who use MA, either in clinical samples or the
general population. Little mental health or substance
abuse research, in general, has been conducted in
Thailand, but recent efforts to address these knowledge
gaps are leading to a burgeoning field of substance use
and mental health research in Thailand, and this study
contributes to that research base. Most notably, an as-
sessment of Thailand’s mental health care services by
the Thai Ministry of Health and the World Health
Organization specified that only 1 % of health-related re-
search published in peer reviewed journals in Thailand
is mental health research [13]. To our knowledge, no as-
sessments of the prevalence and associations between
high levels of depressive symptoms and MA use have
been conducted in rural Chiang Mai province, the
epicenter of an existing MA epidemic. There is a
known association between MA use and depression,
but few resources for the treatment and prevention of
depression and substance use exist in this rural re-
gion. These assessments of individual-level risk factors
that are associated with high levels of depressive
symptoms provide information that could be used to
target prevention efforts among Thai youth who use
MA in this region.
Additional longitudinal and qualitative studies should
be conducted to examine how other individual-level fac-
tors and multiple-level factors (i.e. physical environment,
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social context, substance use, abuse and dependence)
predict the onset of depressive symptoms among Thai
youth to better understand the individual-level and
structural factors driving the onset of depression. Longi-
tudinal studies should also be designed to assess if de-
pressive symptoms precede or are a consequence of
substance use.
Generally, this study could be used as the basis to
begin the evaluation of the effectiveness of treatment
and prevention interventions for depressive symptoms
associated with MA use in Thailand as well as other
low- and middle-income countries. The positive associ-
ation seen in our study suggests that accessible and cul-
turally acceptable mental health care services should be
integrated with drug treatment programs among drug-
dependent youth. The results also indicated that policies
aimed at maximizing resources in rural Thailand to de-
liver more humane and evidence-based approaches to
care and treatment of depressive symptoms among MA
users could contribute to the prevention of MA use and
the reduction of depressive symptoms among Thai
youth.
Conclusion
Associations between MA use and high levels of depres-
sive symptoms were observed. Given the ubiquity of MA
use among adolescents and young adults in this region
of Thailand, resources should target this population for
the provision of culturally acceptable mental health care
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